Login to Your Account

Avanir Reports Positive Results In Neurodex Phase II/III PBA Trial

By Brady Huggett

Wednesday, November 20, 2002
Avanir Pharmaceuticals Inc. reported positive results from one of two planned pivotal trials testing Neurodex in pseudobulbar affect, a somewhat rare tragedy/comedy neurological affliction that affects up to an estimated 1 million people in the U.S. each year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription